<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183440</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0012</org_study_id>
    <nct_id>NCT03183440</nct_id>
  </id_info>
  <brief_title>Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children</brief_title>
  <acronym>PREGRALL</acronym>
  <official_title>A Multicenter Clinical Trial To Assess The Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergies are increasing worldwide affecting 30-40% of the population. Among this, Atopic&#xD;
      Dermatitis (AD) is the earliest and the most common manifestation of allergic diseases&#xD;
      (prevalence 20%). Recent studies have shown that allergies were associated with a disruption&#xD;
      of the gut microbial 'balance' suggesting that the use of nutritional intervention very early&#xD;
      in life may restore an optimal pattern of microflora aiming at improving the host's health.&#xD;
      So far, most human intervention studies have mainly focused on improving postnatal infant&#xD;
      colonization. Our study will test the hypothesis that a maternal antenatal prebiotics&#xD;
      (GOS/inulin) supplementation may be superior to placebo for AD prevention in high-risk&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design :&#xD;
&#xD;
      Inclusion visit at 20 weeks of gestation :&#xD;
&#xD;
        -  randomization&#xD;
&#xD;
        -  start of supplementation (GOS/inulin or placebo)&#xD;
&#xD;
      Phone call at 24 weeks of gestation :&#xD;
&#xD;
        -  checking tolerance&#xD;
&#xD;
        -  checking observance&#xD;
&#xD;
           32 weeks of gestation visit :&#xD;
&#xD;
        -  replenishment of prebiotics&#xD;
&#xD;
        -  collect of AE&#xD;
&#xD;
      Day 1 : assessment of the Transepidermal Waterlos evaluated by a TEWAMETER&#xD;
&#xD;
      Delivery/per partum Visit&#xD;
&#xD;
      At M3 : The national recommendations for the dietary diversification of the child will be&#xD;
      transmitted to the patients&#xD;
&#xD;
      At M6 : evaluation of AD prevalence by parents&#xD;
&#xD;
      At M12 : Pediatric dermatology consultation&#xD;
&#xD;
        -  clinical exam of child&#xD;
&#xD;
        -  the SCORAD&#xD;
&#xD;
        -  the POEM questionnaire&#xD;
&#xD;
        -  prevalence of AD&#xD;
&#xD;
        -  skin prick tests&#xD;
&#xD;
        -  FDQLI score&#xD;
&#xD;
        -  assessment of the Transepidermal Waterlos evaluated by a TEWAMETER&#xD;
&#xD;
        -  prevalence of food allergies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atopic dermatitis prevalence at M12</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>prevalence will be evaluated according to UK party working group criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>atopic dermatitis prevalence at M6</measure>
    <time_frame>at 6 months of age</time_frame>
    <description>prevalence will be evaluated by a phone questionnaire (ISAAC questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atopic dermatitis severity</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>evaluated by the SCORAD (Scoring Atopic Dermatitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atopic dermatitis severity</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>evaluated by the POEM (Patient Oriented Eczema Measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the child and his/her family</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>evaluated by the FDQLI score (Family Dermatitis Quality of life Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the prebiotics in mothers</measure>
    <time_frame>from inclusion to delivery</time_frame>
    <description>evaluated by a questionnaire on digestive status (bloating, stomach aches, diarrhea, flatulences,...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitization with the major allergens</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>skin prick tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the Transepidermal Waterlos</measure>
    <time_frame>at J1 and at 12 months of age</time_frame>
    <description>evaluated by a TEWAMETER(R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food allergies prevalence at M12</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>Prevalence will be evaluated by recording food allergies diagnosed by a physician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>PREBIOTICS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>188 pregnant women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>188 pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PREBIOTICS</intervention_name>
    <description>women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery</description>
    <arm_group_label>PREBIOTICS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>women will daily take placebo (maltodextrin) from inclusion to delivery</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women with an eutocic pregnancy before 20 weeks of gestation&#xD;
&#xD;
          -  women with personal history of atopy diagnosed by a healthcare Professional&#xD;
&#xD;
          -  Women accepting a complete avoidance of dietary supplements containing prebiotics or&#xD;
             probiotics during study supplementation&#xD;
&#xD;
          -  women accepting dermato-pediatric follow-up during the first year of life of the&#xD;
             new-born (Phone calls at 24 weeks of gestation and 6 months of child and a&#xD;
             consultation at 12 months of age)&#xD;
&#xD;
          -  non Tobacco user women&#xD;
&#xD;
          -  women over 18 years&#xD;
&#xD;
          -  women without history of severe gestational diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women not giving up on intake of dietary supplements containing prebiotics or&#xD;
             probiotics during study supplementation&#xD;
&#xD;
          -  women refusing dermato-pediatric follow-up during the first year of the newborn&#xD;
&#xD;
          -  ongoing allergy and/or intolerance to cow's milk proteins&#xD;
&#xD;
          -  term &gt;21 weeks of gestation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastien BARBAROT, Dr</last_name>
    <phone>(0)240084086</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.barbarot@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène AUBERT, Dr</last_name>
    <email>helene.aubert@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume DUCARME</last_name>
      <email>guillaume.ducarme@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Marion FENOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole POIRAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume DUCARME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DOCHEZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Linda LASSEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo Universitaire</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine DUCHANOIS</last_name>
    </contact>
    <investigator>
      <last_name>Delphine DUCHANOIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franck PERROTIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Prevention</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

